Laurion Capital Management LP Sells 66,269 Shares of Adicet Bio, Inc. (NASDAQ:ACET)

Laurion Capital Management LP reduced its stake in shares of Adicet Bio, Inc. (NASDAQ:ACET) by 19.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 275,000 shares of the company’s stock after selling 66,269 shares during the quarter. Laurion Capital Management LP owned 0.86% of Adicet Bio worth $2,830,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the company. JPMorgan Chase & Co. bought a new stake in shares of Adicet Bio in the second quarter worth about $98,000. ProShare Advisors LLC bought a new stake in shares of Adicet Bio in the second quarter worth about $115,000. Deutsche Bank AG bought a new stake in shares of Adicet Bio in the second quarter worth about $128,000. Jump Financial LLC bought a new stake in shares of Adicet Bio in the second quarter worth about $137,000. Finally, New York State Common Retirement Fund bought a new stake in shares of Adicet Bio in the second quarter worth about $184,000. 66.67% of the stock is currently owned by hedge funds and other institutional investors.

ACET traded down $0.08 during mid-day trading on Thursday, reaching $7.94. 7 shares of the company traded hands, compared to its average volume of 81,149. The company’s fifty day moving average price is $7.49 and its 200-day moving average price is $10.14. Adicet Bio, Inc. has a 52-week low of $6.25 and a 52-week high of $17.80.

Adicet Bio (NASDAQ:ACET) last announced its earnings results on Wednesday, August 11th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.18. The company had revenue of $4.81 million for the quarter, compared to analysts’ expectations of $4.50 million. As a group, research analysts forecast that Adicet Bio, Inc. will post -1.89 EPS for the current fiscal year.

ACET has been the topic of several recent analyst reports. Jonestrading reissued a “buy” rating and issued a $33.00 target price on shares of Adicet Bio in a research note on Tuesday, August 24th. Zacks Investment Research raised Adicet Bio from a “hold” rating to a “buy” rating and set a $9.25 price objective on the stock in a research report on Tuesday, October 5th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, Adicet Bio has an average rating of “Buy” and an average price target of $26.47.

Adicet Bio Company Profile

Adicet Bio, Inc is a biotechnology company, which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.

Further Reading: What is the Fibonacci sequence?

Want to see what other hedge funds are holding ACET? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Adicet Bio, Inc. (NASDAQ:ACET).

Institutional Ownership by Quarter for Adicet Bio (NASDAQ:ACET)

Receive News & Ratings for Adicet Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adicet Bio and related companies with MarketBeat.com's FREE daily email newsletter.